Abstract No. 8017Indication: Multiple myeloma Clinical Trial: Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma: CALGB 100104. Presentation Time: Sunday, June 6. Oral session. Notes:Treatment with a maintenance regimen of Revlimid resulted in a 58% reduction in the risk of tumor progression compared to placebo. The median time to progression in the placebo arm was 25.5 months, while median time to progression in the Revlimid arm has not yet been reached. In a separate but similar study also looking at Revlimid maintenance in multiple myeloma patients, Revlimid treatment resulted in a 54% reduction in the risk of tumor progression compared to placebo.